Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.52 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.52 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442130 | 0.83 | CHRNB2 (0.59) | PLOD2PLOD3PLOD1TP53SMN1; SMN2 | |
| SCHEMBL256566 | 0.83 | CHRNB2 (0.59) | PLOD2PLOD3PLOD1TP53SMN1; SMN2 | |
| SCHEMBL27781454 | 0.82 | TRPV1 (0.56) | AKR1C3CYP2C9CYP2C19TRPV1ALDH1A1 | |
| SCHEMBL4350327 | 0.81 | LMNA (0.62) | PLOD2PLOD3PLOD1TP53SMN1; SMN2 | |
| SCHEMBL1981285 | 0.80 | TRPV1 (0.55) | TRPV1ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL28550411 | 0.79 | HTR1A (0.56) | TRPV1ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL1433477 | 0.79 | TRPV1 (0.54) | TRPV1ALDH1A1MAPTCHRNB2CHRNA4 | |
| SCHEMBL30663952 | 0.79 | TRPV1 (0.54) | TRPV1ALDH1A1MAPTCHRNB2CHRNA4 | |
| SCHEMBL28722657 | 0.79 | PLOD2 (0.57) | PLOD2PLOD3PLOD1TP53SMN1; SMN2 | |
| SCHEMBL2376407 | 0.76 | PLOD2 (0.42) | AKR1C3CYP2C9CYP2C19PLOD2PLOD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | AKR1C3 3105/4885CYP2C9 1768/4885CYP2C19 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.